🚨 Kicking off #ECCO2025 with a great ClinCom session led by @J_Kirchgesner
Fantastic talks and amazing people 🙏🏽
19.02.2025 15:01
👍 1
🔁 0
💬 0
📌 0
🚨 Kicking off #ECCO2025 with a great ClinCom session led by @J_Kirchgesner
Fantastic talks and amazing people 🙏🏽
a man smiling in a suit
🚀 Are you passionate about shaping the future of gastroenterology? Join UEG’s Young Talent Group!
Learn more and apply by March 13: https://bit.ly/3p0zyJo
#myUEGcommunity #weareUEG
🎉The latest IBD-Ell newsletter is out!
- New trials added 🌟We've far surpassed 400 summarized trials🌟
- New guidelines
- New cheat sheet with lymphocyte trafficking and anti-integrins
Thanks for following along! www.ibd-eii.com
Subscribe for free anytime 📩
#IBD
It seems like things are picking up towards the end of the year 🏁🏎️
The VIVID-1 trial,mirikizumab in mod-severe #CD
Unlike SEQUENCE this is a double-blind, double-dummy, placebo-controlled AND active-control with ustekinumab AND not all patients had failed TNF
www.sciencedirect.com/science/arti...
The AGA’s first-ever living guideline formoderate-to-severe #UlcerativeColitis led by S Singh, @berkeleydoc.bsky.social, @manasiagrawal.bsky.social, @jhaydek.bsky.social , @ashwinmdibd, @EdwardLoftus2 and myself prioritizes early use of advanced txs over a step-up approach.
ow.ly/t2Ru50UahEi
Ok #GastroSky #IBDSky
Let’s discuss this paper!
Does VDZ become the drug of choice over anti-TNFs for prevention of post of CD recurrence?
Should history of previous biologic failure for active CD affect you choice of post-op prophylaxis?
REPOST to share to the IBD community, patient input pls!
Vedolizumab to prevent postoperative recurrence of Crohn's disease (the REPREVIO RCT)
"Vedolizumab prevented postoperative recurrence of CD & should be considered as a prophylactic treatment in individuals with risk factors for recurrence."
www.thelancet.com/journals/lan...
#GastroSky #IBDSky
go.bsky.app/CuwqDNF
I know I'm a bit late, but here's the updated table of #IBD treatments with their doses & routes of administration with the addition of guselkumalb
Full quality table ➡️ www.ibd-eii.com/ibdcheatsheet/
Induction with subcutaneous guselkumab in mod-severe Crohn's disease
- first phase 3 RCT with SC biologic induction
- includes bio-IR (anti-TNF and VDZ experienced) patients
- treat-trough with SC guselkumab
- effective and safe up to week 48
#IBDSky
@amcollegegastro.bsky.social
Upadacitinib in acute severe ulcerative colitis
- n=25 experience
- potentially useful therapy in ASUC
- still fairly high rates of colectomy (24%)
#IBDSKy
@amcollegegastro.bsky.social
@ibddoctor.bsky.social
Trying this out . Here mainly to learn and interact with IBD colleagues
This is the most important resource for people interested in inflammatory bowel disease
ibd-eii.com
It is run by Beatriz Gros
She is not on BlueSky yet. Please peer pressure her